Aclaris Therapeutics Provides Pipeline Updates for ATI-052 and Bosakitug
Aclaris Therapeutics announced full Phase 1a trial results for ATI-052 and affirmed timelines for upcoming clinical data readouts and a Phase 2b program.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day